Novartis Halts Clinical Trial Evaluating Hydroxychloroquine Against COVID-19 Due to Slow Enrollment

 Novartis Halts Clinical Trial Evaluating Hydroxychloroquine Against COVID-19 Due to Slow Enrollment

Novartis Halts Clinical Trial Evaluating Hydroxychloroquine Against COVID-19 Due to Slow Enrollment

Shots:

  • Novartis has discontinued its clinical trial HCQs due to feasibility of recruitment. The recruitment challenge has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19
  • Novartis will continue to supply HCQ for ongoing IITs on government request globally and will continue to monitor ongoing guidance from health authorities on the further study of HCQ, as well as the decision by the US FDA to stop the EUA of HCQ for COVID-19 treatment
  • Novartis will continue to collaborate to find answers for COVID-19 through various partnerships with multi-stakeholder external consortia

Click here to read full press release/ article | Ref: Novartis | Image: GMP News

Related News: Novartis Signs an Agreement with the US FDA to Evaluate Hydroxychloroquine in Patients with COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post